European Archives - Page 286 of 1177 - European Medical Journal

Illustration of a horizontal vaccine

Roche's twice-yearly MS injection wins FDA approval

The FDA has approved Roche’s subcutaneous injection for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Low-Impact Yoga Eases Urinary Incontinence Symptoms

A study comparing pelvic floor yoga and general exercise found both effective in reducing urinary incontinence in women, with no significant difference between the two approaches.

Allopurinol Improves Safety and Efficacy in Paediatric Leukaemia Maintenance Therapy

Adding allopurinol to maintenance therapy for paediatric ALL improves outcomes and reduces liver toxicity, even in patients with normal 6-MP metabolism.

Long-Term Scans Reveal Brain Changes Linked to Depression

A study from Weill Cornell Medicine, New York, USA has revealed a unique pattern of brain activity that may predispose certain individuals to depression.

First-in-Human Trial of CAR-γδT Cells Shows Promise for Patients With Recurrent Glioblastoma: ESMO 2024

A groundbreaking clinical trial testing QH104, an allogeneic B7H3-targeting CAR-γδT cell therapy, has shown promising results for patients with recurrent glioblastoma.

Breastfeeding Safe for BRCA Carriers After Breast Cancer Treatment: ESMO 2024

A new study provides the first evidence that breastfeeding is safe for women with BRCA mutations after breast cancer treatment.

Pembrolizumab with Chemoradiotherapy Improves Cervical Cancer Survival: ESMO 2024

Results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study have been presented at ESMO 2024, Barcelona, Spain

PEACE-3 Trial Shows Combination Therapy Improves Survival in Prostate Cancer: ESMO 2024

The PEACE-3 trial shows that combining Enzalutamide with Radium-223 improves progression-free survival in metastatic castration-resistant prostate cancer.

Temperature Extremes Worsen Raynaud’s Symptoms in Systemic Sclerosis

A study revealed that the severity of Raynaud’s phenomenon, a common early manifestation of systemic sclerosis, is influenced significantly by ambient temperature.

Early Data Shows CVGBM Vaccine Is Safe in GBM Trial: ESMO 2024

New clinical trial results, presented at ESMO 2024, show that an investigational mRNA-based vaccine CVGBM is safe and well-tolerated in patient with newly diagnosed MGMT-unmethylated glioblastoma (GBM).